Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Radiopharmacology Stories

2014-04-17 16:26:59

Lumiphore Inc., a pharmaceutical leader in bifunctional chelator design, is developing in vivo radio-diagnostic imaging and site-directed radio-therapeutics, using its proprietary bifunctional radionuclide metal-chelation technology; it has received a National Science Foundation Small Business Innovation Research (SBIR) Phase II Grant entitled "Novel macrocyclic chelating groups for use in targeted radioisotope diagnostic and companion diagnostic/therapeutic applications." BERKELEY,...

2014-04-15 12:30:12

Two-part webinar to highlight benefits of molecular imaging in drug development MATTAWAN, Mich., April 15, 2014 /PRNewswire/ -- MPI Research and Translational Imaging Center partners, inviCRO, and 3D Imaging, announce a complementary two-part webinar series that will examine the game-changing benefits of translational research approaches utilizing molecular imaging. Part I of the series, Bridging the Gap with Translational Imaging: Drug Development from Mouse to Man, kicks off on...

2014-04-15 08:28:20

DUBLIN, Apr. 15, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/f9jczp/global_medical ) has announced the addition of the "Global Medical Imaging Reagents Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global Medical Imaging Reagents market to grow at a CAGR of 7.95 percent over the period 2012-2016. One of the key factors contributing to this market growth is the...

2014-04-09 16:25:48

MONTREAL, April 9, 2014 /PRNewswire/ - Jubilant DraxImage Inc., a Jubilant Life Sciences Company, is pleased to announce the appointment of Mr. Michael Rossi as Vice President, Sales and Business Operations, Jubilant DraxImage Inc., with effect from the 21(st) April 2014. Mr. Rossi has worked for GE Healthcare, Life Sciences since 2002, and currently holds the position of General Manager, Global SPECT Business. During his tenure with GE, he has led several commercial organizations...

2014-03-31 20:21:45

DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/c3vlm5/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" [http://www.researchandmarkets.com/research/c3vlm5/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by...

2014-03-23 23:00:43

RnRMarketResearch.com adds Latest Report on “Global Radiopharmaceuticals Market Insight” to its store. Dallas, TX (PRWEB) March 23, 2014 “Purchase the report for 20% discount. Offer valid until 31st March 2014″. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature....

2014-03-20 12:33:23

BERLIN and BOSTON, March 20, 2014 /PRNewswire/ -- Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq(TM). This approval comes only four weeks after receiving marketing authorization for Neuraceq(TM) from the European Commission. http://photos.prnewswire.com/prnvar/20140320/NE87281LOGO Neuraceq(TM) is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with...

2014-03-13 23:25:08

Opportunities for developments, mergers and acquisitions, and investments are just ahead. Louvain-la-Neuve, Belgium, and Lalaye, France (PRWEB) March 13, 2014 This is world's first comprehensive evaluation report and directory of nuclear medicine, written by experts, provides detailed information on products and companies active in this market. It is an almost 800-page report including descriptions of over 300 radiopharmaceuticals and radionuclides and more than 130 detailed profiles...

2014-03-04 08:31:27

SAINT-GENIS-POUILLY, France, March 4, 2014 /PRNewswire/ -- Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE. The orphan drug designation has been granted by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of Gallium-68 DOTATATE as a diagnostic...

2014-03-04 08:31:24

AAA to acquire 100% of IEL in newly issued AAA shares SAINT-GENIS-POUILLY, France, March 4, 2014 /PRNewswire/ -- - The acquisition gives AAA its first direct sales presence in the UK and Ireland, expands its specialist nuclear medicine capabilities and gives it the rights to IEL's licensed SPECT radiopharmaceutical diagnostic product, IELMAG3 - IEL generated sales of almost GBP6.77 million for the year ended 31 December...